In high-throughput swine operations, the liquid concentrate is incorporated into water-soluble oral powders and feed premixes at the post-weaning stage. The as-received Huoqi Perfusion Solution Veterinary Grade API is first normalized against the certificate of analysis dry solids value; if the CoA reports 10.0–12.5% w/w dry matter, a production batch record typically adjusts the as-received liquid inclusion to 0.8–1.4% w/w of the finished premix so that the dry solids contribution remains within 0.08–0.18% w/w. This is not a fixed pharmacopoeial limit but a working range documented in master manufacturing instructions for viscous botanical extracts of similar composition; if the CoA has not been received, published data for this specific configuration is limited and the addition must be recalculated against the incoming dry matter result. The liquid is sprayed through a fan nozzle at 2.5–3.5 bar into a horizontal ribbon blender with a working volume of 800–1,200 L, after an initial dry blend of dextrose monohydrate, sodium citrate dihydrate, and fumed silica at 1.0% w/w to reduce droplet coalescence on the steel surfaces. Field-scale observations in such blenders show that direct injection of the liquid onto the tops of the powder bed without an internal premixture creates agglomerates above 850 µm that then survive the final sifting step; the standard corrective action is to prepare a 5 kg manual premix of the API with fumed silica and carbonate-coated dextrose before introducing it to the main mixer.

Release testing for the swine premix segment includes loss on drying by ISO 6496:1999 after 4 h at 103°C, sieve analysis using a 500 µm aperture under ISO 565:1990, and blend uniformity by near-infrared spectroscopy calibrated against a blend homogeneity acceptance value of ≤ 15% relative standard deviation according to the premix section of the marketing authorization file. The manufacturing building operates under a current Good Manufacturing Practice framework for veterinary medicinal products set out in Regulation (EU) 2019/6 and, where the product is designated as a feed-related intermediate, under the feed hygiene requirements of Regulation (EC) No 183/2005. Terminal product forms are water-soluble powders packed in heat-sealed polyethylene terephthalate/aluminum/low-density polyethylene sachets and medicated premixes for on-farm mixing at 1–3 kg per tonne of complete feed. The operational boundary is that the API liquid must not be stored at below 2°C because freeze-thaw cycles produce sediment that blocks dosing pumps.

Which Granulation Parameters Preserve Liquid API Distribution in Broiler Drinking-Water Powders?

In broiler integrations, the drinking-water administration route requires a fully wettable granule that disintegrates in 60 seconds at 25°C without generating a non-dispersible film. The API liquid is introduced in a fluid-bed granulator as a top-spray binder solution after being diluted with purified water and hydroxypropyl methylcellulose at 0.3–0.5% w/w of the binder mass. The liquid addition rate has a process window of 180–240 g/min for a 200 kg bed; below the lower bound, the spray dries before wetting the lactose monohydrate and corn starch core, causing API to accumulate in the filter bags rather than on granules. Above the upper bound, the bed delta pressure rises above 1,800 Pa, and the product mass shifts from free-flowing granules to overwet agglomerates that require re-milling. The inlet air temperature is held at 60–65°C, while product temperature is maintained at 34–38°C because the dry solids fraction of the liquid begins to darken and lose water-soluble polysaccharide content when product temperature exceeds 42°C for more than 20 minutes in standard batching.

Release specifications are anchored to Ph. Eur. 2.9.3 disintegration for granules administered by drinking water, Ph. Eur. 2.9.5 mass uniformity for single-dose sachets, and USP <905> content uniformity where batch size exceeds 250,000 units. Residual solvent testing is irrelevant because the granulation is aqueous; the facility instead tests microbial quality by Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 with limits for total aerobic microbial count at ≤ 10³ CFU/g and absence of Escherichia coli in 1 g. Terminal product types include effervescent granules, film-coated granules packed in aluminum foil-lined pouches, and oral solution concentrates for proportioner dosing at 100–500 mL per 1,000 L of drinking water. The main operational boundary is that the finished granules must not be exposed to relative humidity above 60% during packaging without a desiccant load of at least 2 g silica gel in a 100 g pouch.

In ruminant herd health protocols, oral drench solutions and molasses-based lick blocks are specified when individual injection is labour-constrained and drinking-water dosing is unreliable because of variable water intake. The Huoqi Perfusion Solution Veterinary Grade API is incorporated into an oral drench vehicle consisting of propylene glycol, sodium carboxymethylcellulose, potassium sorbate, and purified water; the liquid API is metered at 1.0–2.0% v/v of the finished drench, with viscosity adjusted to 150–350 mPa·s at 20°C using a Brookfield viscometer spindle 2 at 50 rpm so that the product remains pourable through standard drenching guns fitted with 3 mm nozzles. In molasses-based blocks, the addition ratio is limited to 0.4–0.6% w/w of the cooked molasses base before cooling; above 0.6%, the forming stage in 5–10 kg plastic tubs develops surface syneresis and poor block integrity within 72 h of ambient storage at 30°C.

The process for a 1,000 L drench batch uses a bottom-entry high-shear mixer to disperse the liquid API into the propylene glycol premix, followed by pH adjustment to 5.5–6.5 with dilute hydrochloric acid or sodium hydroxide before filtration through a 10 µm polypropylene cartridge. The molasses block process introduces the API after the molasses has cooled to 55–60°C; prolonged incorporation above 70°C leads to darkening and loss of pH-dependent solubility of the extract. Compliance for these products is established under Regulation (EU) 2019/6 for veterinary medicinal products and, for food-producing species, maximum residue limits under Regulation (EU) No 37/2010 must be reflected in the withholding period section of the marketing authorization. Terminal product forms are ready-to-use oral drenches in 1 L and 5 L high-density polyethylene bottles, molasses blocks in 5 kg and 20 kg tubs, and concentrated oral gels in laminate tubes for use in automatic dosing systems. A known operational boundary is that the liquid API should not be acidified below pH 4.0 before centrifugation, because the extract precipitates and clogs the 10 µm filters.

Injectable Perfusion Solution Segment: Container Closure Integrity and Sterility Assurance

For sterile injectable presentations, the veterinary-grade API is processed as a large-volume perfusion solution or a small-volume injection in Class 5 cleanrooms under EU GMP Annex 1 and ISO 14644-1:2015. The as-received liquid concentrate is diluted with Water for Injection to a target dry solids concentration of 0.05–0.10% w/v, and the solution is adjusted to isotonicity with sodium chloride at 0.85–0.90% w/v; pH is maintained at 6.0–6.8 using phosphate buffer at 5–10 mM. The solution is chilled to 8–12°C before filtration through a 0.45 µm polyvinylidene fluoride pre-filter and a 0.22 µm polyethersulfone final filter; filtration pressure differential is maintained below 0.8 bar to avoid rheological gel formation on the membrane surface, a failure mode observed when unfiltered concentrate batches with high polysaccharide content are processed at 20–25°C without a pre-filter.

Terminal sterilization is validated at 121°C for 15 minutes when the formulation has a D-value of 1.5–2.0 minutes for Bacillus subtilis spores; if thermal degradation of the dry solids fraction exceeds 5% when measured by size-exclusion chromatography after autoclaving, the process is switched to aseptic filtration in a barrier isolator with a sterility assurance level of 10⁻⁶. Container closure integrity is verified by USP <1207> with a laser-based headspace analysis threshold of Δ O₂ <0.5% after 24 h; particulate matter is assessed by Ph. Eur. 2.9.19 and USP <788> with limits for ≥ 10 µm and ≥ 25 µm particles per container as defined by the intended route. The primary packaging is either Type I borosilicate glass ampoules filled at 2 mL and 10 mL under nitrogen, or a multilayer polyolefin non-PVC bag for large-volume perfusion at 500 mL; the bag material must pass USP <661.1> and has a documented lower oxygen barrier than glass, which shortens the shelf life to 12 months at 25°C/60% RH unless an aluminum overpouch is used. The operational boundary is that silicone oil used in glass prefillable syringes is not compatible with the API at concentrations above 0.2 mg/mL because subvisible particle counts increase above the compendial threshold after 30 days at 40°C; therefore, silicone-free cartridges or glass ampoules are specified for this formulation.

If a Tablet Formulation Is Required Without an Aqueous Granulation Step

When solid oral dosage forms in companion animal medicine require a non-capsule presentation, the liquid API is sprayed onto a porous excipient blend to avoid the aqueous granulation route and its associated drying thermal load. The as-received liquid is mixed with a 1:1 w/w blend of microcrystalline cellulose and colloidal silicon dioxide in a high-shear granulator at impeller speed 120–150 rpm and chopper speed 1,000–1,500 rpm for 5–8 minutes; the liquid load is held at 5–8% w/w of the total blend so that the final tablet formulation contains 2.5–4.0% w/w of the liquid API, equivalent to 0.25–0.50% dry solids in the tablet core. The resulting flowable powder is then blended with sodium starch glycolate at 2.0%, magnesium stearate at 0.75%, and anhydrous dibasic calcium phosphate in an 800 L bin blender for 15 minutes at 10 rpm.

Compression is performed on a 27-station rotary tablet press at 60,000–90,000 tablets/h with a compression force of 8–14 kN; hardness is controlled to 50–80 N and friability to ≤ 0.5% by Ph. Eur. 2.9.7. Tablet weight variation follows Ph. Eur. 2.9.5 for uncoated tablets, and dissolution testing is performed by USP <711> Apparatus 2 at 50 rpm in 900 mL phosphate buffer pH 6.8; the Q value is set at not less than 75% released at 45 minutes in the registered specification. Coating is an aqueous film-coating step in a perforated pan at 38–42°C product temperature; the tablet cores must have a moisture content below 2.0% w/w by USP <921> before coating to prevent twinning and logo bridging. The main operational boundary for this direct-compression route is the hygroscopicity of the API dry solids: if relative humidity in the compression suite exceeds 55%, the powder blend picks up moisture and the ejection force increases above 2,000 N, causing sticking to the punch faces. Terminal product types are uncoated tablets, film-coated tablets for companion animal administration, and capsules made by filling the same final blend into size 0 hard gelatin capsules at 500 mg total fill weight. Regulatory release for these solid dosage forms requires batch homogeneity testing under the relevant marketing authorization and stability storage at 25°C/60% RH and 40°C/75% RH according to ICH Q1A(R2) and VICH GL3 for shelf-life assignment.

Cross-Contamination Control Fails When Premix Flush Quantities Are Calculated Solely by Volume

Medicated premix production in multi-species feed mills introduces a carryover risk that is controlled only when the flush sequence is calculated by active ingredient mass, not equipment volume. The API liquid is added to a carrier consisting of ground corn cob, calcium carbonate, and mineral oil at 0.5–1.0% w/w of the premix; because the as-received liquid has a dry solids fraction that varies by ± 0.5% between supplier batches, the liquid addition must be corrected by mass balance after each coil of drums is sampled. The mixing sequence in a 2,000 kg twin-shaft paddle mixer includes a 60-second dry blend, 120-second liquid spray phase, and 180-second wet mixing phase; the mixer discharge gate must not be opened until all liquid has been adsorbed onto the carrier. Homogeneity is tested according to Commission Regulation (EC) No 152/2009 Annex III for the determination of a non-uniformity coefficient; field data from three production campaigns indicates that a flush batch of 25 kg is sufficient to reduce residual API in the next non-medicated batch below the limit of quantification when the premix concentration is 0.1% w/w, whereas a volume-only flush of 10 kg fails in bottom-gated mixers due to material trapped in the dead zone under the discharge gate.

Regulatory compliance is established under Directive 2001/82/EC or Regulation (EU) 2019/6 for authorized veterinary medicinal premixes, plus EU Regulation (EC) No 183/2005 on feed hygiene for non-medicinal feed materials; in export markets, the manufacturer must document equivalence of the carryover limits to those in the current US FDA CVM 21 CFR Part 225 and Part 558 when medicated feed applications are submitted. Terminal products are 25 kg multiwall paper sacks with an inner polyethylene liner, or 5 kg water-soluble pre-weighed packs for direct use. The operational boundary is that the API liquid must not be stored below 2°C or above 30°C in the premix manufacturing area; freeze-thaw cycles produce sludge that blocks dosing pumps, and storage above 30°C for more than 14 days increases microbial count in the liquid concentrate beyond the premix specification of 10⁴ CFU/mL.